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Background: Parents and carers of children with eczema often underuse emollient therapy, essential to repairing
and protecting the defective skin barrier in atopic eczema. Educational interventions delivered by specialist
dermatology nurses in hospital settings have been shown to improve emollient use and reduce symptoms of
atopic eczema, but benefits of community-based interventions are uncertain. Support and information about
appropriate care may often be inadequate for patients and carers in the community.
Methods: A multifaceted educational support programme was evaluated as a method of increasing emollient use
and reducing atopic eczema in children. Support provided for parents and carers included an educational DVD,
online daily diary and telephone helpline. The before and after study included 136 British children and their parents,
providing baseline and 12 week follow-up data while receiving the programme. Measures included emollient use,
POEM and PEST scores, and cost of care.
Results: Average emollient use increased by 87.6 g (95% CI: 81.9 to 119.5 g, p = 0.001) from baseline with the change
being immediate and persistent. The POEM score reduced on average by 5.38 (95% CI: 4.36 to 6.41, p = 0.001), a 47%
reduction from baseline. Similarly the PEST score reduced on average by 0.61 (95% CI: 0.47 to 0.75, p = 0.001), a 48%
reduction from baseline. Sleep disturbance was reduced by 1.27 nights per week (95% CI: 0.85 to 1.68, p = 0.001) and
parental feeling of control improved by 1.32 points (95% CI: 1.16 to 1.48, p = 0.001). From the NHS perspective, the
programme was cost neutral overall within the study period.
Conclusion: A community-based multifaceted educational support programme greatly increased emollient use,
reducing symptoms of atopic eczema and general practitioner contacts, without increasing cost. Significant benefits
may accrue to the families and carers of children with atopic eczema due to improved sleep patterns and greater
feeling of control. PEST, a new simple measure of acute and remitting atopic eczema severity designed to help parents
and children to monitor and manage eczema, merits further evaluation.
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Atopic eczema (synonym atopic dermatitis) in children
is unpredictable in its course and may have a profound
impact on the quality of life [1-3] of patients and their
family, as well as being time-consuming for healthcare
professionals to manage. However, the primary care set-
ting is not often well equipped for patient education and
support. Twenty years ago, in 1993 a survey of members
of the National Eczema Society asked what members
wanted healthcare professionals to do to improve the
control of childhood atopic eczema [4]. The majority
wanted more time to be spent explaining the nature of
eczema and advice about how to use the treatments pre-
scribed. In 83% of consultations with general practi-
tioners (GPs) and 74% of first consultations with a
dermatologist, the expectations of parents/patients had
been only partially met or not met at all.
Education of parents and children with atopic eczema
is now recognised as one of the most important inter-
ventions in the management of atopic eczema [1,5-10].
The largest RCT of an education programme was
conducted in Germany, including 823 children or
adolescents with atopic eczema and their families [7]. A
six-week education programme for the management of
moderate to severe atopic eczema was evaluated, with
dermatological, nutritional and psychological facets; it
was delivered as a two hour, once-weekly session by a
multi-professional team. At one year, improvement in
the severity of atopic eczema (SCORAD) in children
who received the education programme was significantly
greater than in the control group. There were also
significant improvements in subjective assessments of
severity, itching behaviour and emotional coping in the
group receiving education compared to control.
A cost-effectiveness analysis was performed using the
data from the German trial as part of the NICE guide-
lines for treatment of atopic eczema [2]. This demon-
strated that if an atopic eczema education programme,
similar to that detailed in the German RCT could be
provided at less than about £800 per child, then it would
be highly likely to be cost effective. NICE also concluded
that if a less-resource intensive (and less effective)
programme could be implemented in the NHS then this
was also likely to be cost-effective.
The impact of specialist dermatology nurse-led educa-
tion has been evaluated in children with mild/moderate
atopic eczema [5,6,11]. These studies showed a signifi-
cant improvement in the control of atopic eczema in
children receiving education. For example Cork and
colleagues [6] found that 24% of children with atopic
eczema were receiving no emollient treatment, with an
average use of emollient of just 54 g per week. Derma-
tology clinic-based specialist nurse-led educational inter-
vention resulted in an 800% increase in the use ofemollients with a corresponding 89% reduction in the
severity of the atopic eczema. Although much less
resource intensive than the German RCT, these studies
were in populations of children with less severe, mild/
moderate atopic eczema.
There have been no comparisons of different educa-
tion programmes for atopic eczema in children apart
from a recent comparison of face-to-face care and an e-
health intervention [12]. Children (with their parents)
and adults with moderate severity atopic eczema
attended for a first consultation with a dermatologist
and specialist dermatology nurse. Subsequently, they
were randomised to face-to-face follow-up treatment in
the dermatology department or to internet-guided moni-
toring and on-line self-management training. There were
no significant differences in severity of the atopic eczema,
quality of life and intensity of itching between the two
groups. Compared to routine care, the e-health interven-
tion led to non-significant changes in health and broader
societal costs although estimates were imprecise.
Atopic eczema arises as a result of gene-environment
interactions leading to a defective skin barrier [13-15].
Thus, emollient creams, ointments and wash products are
the first line treatment to repair the skin. In mild atopic
eczema, effective management consists of complete emol-
lient therapy plus occasional treatment of flares with mild
potency topical corticosteroids [2,16]. Educational inter-
ventions for atopic eczema are provided most commonly
in the secondary care hospital setting, while the large ma-
jority of children have mild atopic eczema and are treated
in primary care [17,18]. Guidelines emphasize the import-
ance of using sufficient emollient: 250 to 500 grams per
week [2], the more emollient being used the less the need
for mild potency topical corticosteroids [5]. However, the
actual use of emollients in the UK is far less than this
recommended amount.
Rather than designing an intervention that influenced the
selection of prescribed products, we designed a study to as-
sess and improve emollient use and outcomes in children
who had currently been prescribed a proprietary emollient,
E45 Cream (Reckitt Benckiser Healthcare, UK). Using this
design, the amount of emollient could be tracked, along
with co-treatment over a 3-month period, allowing the sup-
port programme to be assessed. The support programme
used a multifaceted approach since evidence from a num-
ber of fields supports an integrated, supportive approach
for patients as more effective than single or simple mea-
sures in achieving behavioural change [19-21].
Methods
Objective
To investigate the effectiveness of a multifaceted educa-
tional support programme to increase emollient use and
reduce atopic eczema symptoms in children.
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Using a before and after study design, a purpose-
designed multifaceted educational support programme
(ESP) was provided for parents or carers of children with
atopic eczema. The programme included an educational
DVD, easy-to-use diaries to record eczema condition
and daily use of emollients, and telephone support line
with dermatology nurses provided regular and on-
demand phone support. Data were collected in a 2-week
baseline period and 12-week follow-up period (3 months
in all). Parents and carers were also asked to recall use
of health services in the 12 weeks prior to starting the
programme.
Study population
Parents of children were identified by the Bounty® Data-
base system operating in the United Kingdom, and sent
an email introducing the study. Those interested in par-
ticipating contacted a free telephone call centre number
for further details and to assess eligibility. Parents pro-
viding informed consent verbally were provided with a
link to the study website and the child’s GP was notified
of their participation in writing. The study website
provided a second confirmatory electronic consent and
access to a baseline diary.
Eligible children were male or female aged 3 months
to 6 years; with mild to moderate atopic eczema; and,
currently using E45 Cream as their primary emollient.
Children were ineligible where there was a planned ab-
sence from home for more than 21 days during the
study period; where parents were unable to complete the
patient diaries or questionnaires; if receiving systemic
medication (e.g. Ciclosporin A, methotrexate) or UV
light treatment for their atopic eczema in the 3 months
preceding the study; if receiving oral steroids or any new
atopic eczema-specific treatment regimen in the 4 weeks
preceding the study.
In the original design, referral in the preceding
3 months to a Dermatologist, a Specialist Dermatology
Nurse or a GP with a Specialist Interest in Dermatology
or receiving specific atopic eczema education or training
was an exclusion criterion. However it was not possible
pragmatically to exclude patients with a prior visit to an
eczema specialist and these were subsequently included.
The analysis plan was modified prospectively to include
these subjects, with the effect of inclusion explored by
sensitivity analysis.
Discussion with the National Research Ethics Service
(NRES) established that Independent Ethics Committee
approval was not required. The study was considered to
be non-interventional service evaluation assessing pa-
tient support as an aid to ensure use of emollient
according to NICE recommendations and thus not re-
quiring regulatory approval. Products prescribed topatients were not influenced by the study, only the
frequency of their use.
Multifaceted educational support programme
Parents or carers (‘parents’) reported baseline data
(weeks −2 to 0) on the study website. On completion of
the baseline assessment, parents received by mail an
introductory support pack designed to educate, motivate
and correct the use of emollient therapy, followed by the
first of several telephone interviews and counselling
sessions by a dermatologist nurse specialist. Depending
on the support needs of the family, further telephone
support calls were made on demand, along with optional
SMS messaging reminding parent or carers of the
patient support eczema management regime.
The support pack included an instructional DVD on the
use of emollients in eczema management, featuring the
lead dermatology nurse; a booklet on eczema manage-
ment co-written with the National Eczema Society,
London; a hooded towel designed for child use after bath-
ing to improve the experience of emollient application,
and a set of daily diaries. Each diary covered a 4-week
period and the total follow-up period covered was
12 weeks. On completion, diaries were returned to the
agency conducting the study (Partizan International,
London, UK). Components of the support programme are
available online [22].
During the study, prescribing of E45 Cream by the
child’s GP continued in accordance with routine clinical
practice. Parents were encouraged to use E45 Cream by
depressing the pump 3 times (approximately 12 g), three
times a day, or the equivalent for non-pump packs
which is 3 level teaspoons (approximately 12 g), three
times a day. If followed, this advice would provide
approximately 250 g per week. Parents were advised
repeatedly to avoid soap and all harsh detergent-based
products, replacing these with emollient wash products.
Outcomes
Baseline and follow-up measures included the following:
Emollient use (grams per week) was estimated in an
initial telephone questionnaire based on the emollient
pack weight and how long this would usually last. This
provided the only estimate of baseline use, in order to
avoid the risk of the parent altering their pre-
programme practice. Once the support programme had
begun, emollient use was captured (as at baseline) at
each 4-weekly telephone assessment. Additionally, the
number of pumps of emollient used daily was recorded
in diaries and the weekly use estimated directly.
Severity of eczema was captured using the POEM
(Patient Oriented Eczema Measure) [23]. This recorded
the days in a week affected by seven signs of eczema:
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skin, and by sleep loss.
Additionally a new simple measure called the Patient
Eczema Severity Time (PEST) score was developed for
this study, reflecting observations in the clinic that
patients’ own summative severity perceptions very
closely correlated with conventional severity scores. Thus
a simple daily score of ‘overall unhappiness’ with eczema
might provide a form of monitoring and feedback to
patients and their carers as well as sensitively integrating
the sum of eczema experience over time, in a condition
with relapsing and remitting severity patterns. The daily
diary provided pictorials for users ranging from ‘not at all
unhappy’ to ‘extremely unhappy’ scoring 1 to 5
respectively. The PEST score was also designed to be
easy for parents to assess in patients too young to
vocalise this for themselves (see Figure 1).
Healthcare contacts. The number of GP visits by
patients in relation to their eczema was recorded; in
the 12 weeks prior to and during the 12 weeks of the
programme. Eczema-related visits to a dermatology
specialist were recorded during the programme period.
Parent measures. The level of control the parent felt in
managing the child’s eczema was captured by telephone
questionnaire at baseline and during the programme
phase. It was scored from 1 to 5, with 1 being ‘not in
control’ to 5 ‘fully in control’.
Concurrent medication. Telephone surveys recorded
any concurrent treatments used during baseline and
the 12 week follow-up, with particular attention to
topical corticosteroid use.Statistical analysis
There were no reliable estimates for the underuse of
emollient and thus potential for improvement in the
study population, consequently no formal powerFigure 1 Emollient use before and during the intervention.calculation was performed. The per-protocol intention
was to recruit 150 eligible children age 3 months to
6 years. Given the matched (before-after) data design
this would give adequate study power to find small stan-
dardized effects in continuous measures (post-hoc: 90%
power to detect at effect size of 0.27).
Summary measures were reported for study measures
at baseline and in each of the follow-up weeks. Average
values were estimated for the 12 week follow-up period
to reflect the average effects of the patient support
programme and to assess the before-after effect.
Changes in paired continuous measures were estimated
using the bootstrapping method (with 1,000 replications)
to avoid parametric assumptions and changes in paired
proportions were evaluated using Fisher’s exact test. Pa-
tients with complete data at all points contributed to
average period values and differences.
Economic analysis
Incremental within-study cost analysis was performed
from the NHS perspective using nationally reported unit
costs for resource items for 2011. The emollient (E45
Cream POM 500 g) was costed at the average English
Prescription Pricing Authority-reimbursed rate of £4.89
[24]; GP visits were costed at £36 per visit [25] [D]. The
cost of providing the ESP programme was estimated to
be £32 per child based on a resource analysis of provid-
ing the service.
Results
Study population
Programme diaries were completed by 136 British chil-
dren between August 2011 and March 2012. Subjects
were evenly split as Caucasian and non-Caucasian and
all parents spoke adequate English. One child was ex-
cluded as they did not provide any baseline data, leaving
135 children evaluable. Of these, 18 subjects visited an
eczema specialist in the three months prior to joining
the programme and thus might have already received
additional education on eczema management: these were
excluded in a sensitivity analysis.
During the baseline period (−2 to 0 week) the average
weekly use of emollient was 79 g (range 4 g to 700 g)
(see Table 1). Just 4 children (3%) received at least the
NICE minimum dose of 250 g and 12.9% received
125 g/wk. The baseline POEM score was 11.3 (SD: 6.3),
and PEST score 2.3 (SD 0.8), 40% and 32% of maximum
on each respective scale. Children experienced dryness,
redness and itching on average 5.7, 4.1 and 4.7 days a
week. Sleep disturbance occurred on average 2.4 nights a
week with 21% of parents reporting sleep disturbance at
least one night in two. Parental sense of feeling in con-
trol of eczema scored an average of 3.3 where 22% of
parents reported low levels of control (scoring 1 or 2).
Table 1 Changes in emollient use and measures of eczema severity
Baseline1 1-4 weeks 5-8 weeks 9-12 weeks Mean change2
Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) N Mean 95% CI3 N p3
Emollient Use (g/wk)4
Daily diary - 165.2 (96.4) 135 168.4 (113.2) 135 167.8 (109.5) 135 87.6 (81.9 to 119.5) 132 0.001
Time to use 79.2 (79.2) 132 173.5 (114.3) 122 195.2 (112.1) 128 197.4 (106.5) 129 110.0 (94.6 to 131.3) 115 0.001
Severity Scores
POEM5 11.34 (6.27) 135 7.52 (5.71) 135 5.50 (5.05) 135 4.85 (5.04) 135 −5.38 (−6.41 to −4.36) 135 0.001
PEST6 2.26 (0.81) 135 1.82 (0.73) 135 1.59 (0.78) 135 1.53 (0.68) 135 −0.61 (−0.75 to −0.47) 135 0.001
Individual Scores
Dryness [A] 7 5.66 (1.97) 135 4.09 (2.38) 135 3.22 (2.45) 135 2.86 (2.39) 135 −2.28 (−2.67 to −1.90) 135 0.001
Redness [B] 7 4.12 (2.44) 135 2.74 (2.42) 135 1.95 (2.18) 135 1.82 (2.13) 135 −1.95 (−2.37 to −1.53) 135 0.001
Itchiness [C] 7 4.73 (2.54) 135 3.38 (2.56) 135 2.63 (2.67) 135 2.37 (2.53) 135 −1.94 (−2.36 to −1.52) 135 0.001
[A] + [B] + [C] 14.51 (5.64) 135 10.21 (6.35) 135 7.79 (6.24) 135 7.04 (6.24) 135 −6.17 (−7.17 to −5.20) 135 0.001
Sleep disturbance 7 2.36 (2.44) 135 1.49 (2.12) 135 0.98 (1.62) 135 0.80 (1.59) 135 −1.27 (−1.68 to −0.85) 135 0.001
Bleeding7 1.34 (1.99) 135 0.68 (1.35) 135 0.42 (1.05) 135 0.33 (1.03) 135 −0.86 (−1.18 to −0.56) 135 0.001
Weeping or oozing7 0.86 (1.74) 135 0.40 (1.15) 135 0.24 (0.87) 135 0.18 (0.76) 135 −0.59 (−0.87 to −0.35) 135 0.001
Cracking7 2.44 (2.50) 135 1.41 (1.90) 135 1.02 (1.79) 135 0.89 (1.81) 135 −1.34 (−1.77 to −0.97) 135 0.001
Flaking7 2.26 (2.63) 135 1.37 (1.96) 135 0.80 (1.47) 135 0.76 (1.57) 135 −1.28 (−1.69 to −0.85) 135 0.001
Roughness7 5.49 (2.07) 135 4.25 (2.40) 135 3.32 (2.54) 135 3.56 (2.10) 135 −1.93 (−2.33 to −1.55) 135 0.001
Severity7 4.65 (5.16) 135 2.49 (3.86) 135 1.68 (3.17) 135 1.39 (3.02) 135 −2.80 (−3.63 to −2.03) 135 0.001
Other
Parental Control8 3.30 (0.99) 135 4.43 (0.66) 134 4.61 (0.57) 135 4.81 (0.41) 135 1.32 (1.16 to 1.48) 134 0.001
GP Visits1 1.90 (2.13) 135 0.46 (0.54) 135 0.25 (0.44) 135 0.13 (0.36) 135 −1.06 (−1.49 to −0.70) 135 0.002
Steroid Prescribed (%)9 51/135 (37.8%) 73/135 (54.1%) 82/135 (60.7%) 82/135 (60.7)% 20.8% (8.9% to 32.1%) 135 0.001
1 Weeks −2 to 0, except GP visits which included the previous 12 weeks to week 0.
2 The mean change is the average of the programme period scores minus the baseline period score in subjects with complete data.
3 Estimated by bootstrapping with 1,000 replications.
4 Emollient use was estimated using two methods: the time to use a reported weight of emollient (500 g); and, a daily diary record of counts of pumps of emollient used by weight; – the latter method was not
available for the baseline period.
5 POEM score from 0 to 28, including seven signs of eczema at four levels of frequency in the past week at the end of each period.
6 PEST score, the child’s unhappiness with eczema: score 1 (not at all) to 5 (very unhappy), daily diary score averaged over each period.
7 Number of days in the previous week has the child had this sign of eczema: score 0 to 7 days, at the end of each period.
8 Parental confidence in managing the child’s eczema: score 1 (not being in control) to 5 (being totally in control), at the end of each period.
9 Proportion of children prescribed topical corticosteroids during each period.
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Figure 2 Patient-Orientated Eczema Measure (POEM) before
and during the intervention (means and 95% confidence
intervals shown).
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Change in emollient use
Diary recorded emollient cream use increased significantly
during the 12 weeks of the programme (see Figure 2 and
Table 1). On average emollient use increased by 87.6 g
(95% CI: 81.9 to 119.5, p = 0.001) with the change being
immediate and persistent with 8.9% of children receiving
250 g/wk at 12 weeks and 61.5% receiving 125 g/wk.
Emollient use was also estimated, as at baseline, as the
time taken in each period to use a prescribed emollient
cream pack of known weight. The estimated increase in
emollient was higher at 110 g/wk (95% CI: 94.6 to 131.3,
p = 0.001) although only 85% of parents reported this
measure.
From a baseline of 37.8% of patients, prescription of
topical corticosteroids increased significantly by 20.8%
(95% CI: 8.9% to 32.1%, p = 0.001) during the programme.
The volume of use of steroid was not recorded but hydro-
cortisone 1% accounted for 70% of total use and
clobetasone butyrate 0.05% (in various preparations) for
25%. Although topical steroids were prescribed, parents
reported that they used these in minimal quantities due to
concerns about side effects. An increase in topical steroid
use was not planned as part of the educational support
provided, but often arose in telephone support sessions.Figure 3 Patient Ezcema Severity-Time Score (PEST) before and durinChanges in measures of eczema severity
Eczema severity reduced significantly during the
12 weeks of the programme. The POEM score reduced
on average by 5.38 (95% CI: 4.36 to 6.41, p = 0.001), a
47% reduction from the baseline score (see Figure 3 and
Table 1). Individual signs of eczema consistently
followed the pattern of improvement seen in the aggre-
gated POEM score (see Table 1).
Similarly the PEST score reduced on average by 0.61
(95% CI: 0.47 to 0.75, p = 0.001), a 48% reduction from
the baseline score (see Figure 4 and Table 1). During the
programme, 45.9% of children were reported as having
an average POEM score of 0 to 2 compared to 4.4% at
baseline; similarly 56.3% of children were reported with
a PEST score of 1 compared to 13.3% at baseline. POEM
and PEST scores were strongly correlated with Pearson
correlation coefficients at baseline, 4, 8, and 12 weeks of
0.56, 0.51, 0.63 and 0.71 (P < 0.01 in all instances).
Of particular note are two measures which may have
broader implications for the families of children suffer-
ing with eczema. Loss of sleep if persistent may have
significant knock-on consequences for the health and
well-being of family members. On average, the number
of nights per week experiencing sleep disturbance was
reduced during the 12 week programme by 1.27 nights
(95% CI: 0.85 to 1.68, p = 0.001), a halving of the base-
line level of disturbance. Secondly, parental feeling of
control of their child’s eczema improved by 1.32 points
(95% CI: 1.16 to 1.48, p = 0.001) with 91.5% of parents
reporting the highest level of control.
Health economic outcomes
Costs of care in the periods preceding and during the pa-
tient support programme are tabulated in Table 2. There
was a statistically significant increase in the cost of emol-
lient by about £10 using the diary method, or about £13
using the ‘time-in-use’ method. GP visits fell on average
by about 1 visit per child (Table 1) leading to no overall
or significant change in net cost. The finding was similar
regardless of the method of estimating emollient use.
Sensitivity analysis
Analyses were repeated in 117 subjects, excluding 18
subjects who had visited an eczema specialist in the threeg the intervention (means and 95% confidence intervals shown).
Figure 4 Patient Ezcema severity-time score (PEST) graphic.
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findings were unchanged in this subgroup (Table 3).
Discussion
Given the considerable underutilisation of emollients for
atopic eczema in children, effective training for parents in
the use of topical therapy is a key issue. Our experience
within the dermatology clinic has underlined the import-
ance of a comprehensive approach to support and educa-
tion, including printed, verbal and visual components to
achieve the broadest effect [6]. The study findings demon-
strate the potential utility of providing a patient-centric
support package to enhance concordance with treatment
goals and improve patient outcomes.
Primary care practitioners are sometimes concerned
about the practicality of delivering multifaceted interven-
tions in routine care. The current study demonstrates that
a coherent multifaceted programme, delivered at a dis-
tance using a specialist dermatology nurse, may be a cost-
neutral use of NHS resources. Primary care commissionersTable 2 Costs of care in the baseline and programme periods
Pre-Programme1 Programme2
Mean (SD) Mean (S
Cost (£, 2011)
Programme 32.00
Emollient [A] 9.29 (9.30) 19.57 (12
Emollient [B] 9.72 (9.69) 22.64 (12
GP visits 68.53 (76.70) 30.40 (31
Overall cost [A] 78.29 (79.34) 82.66 (34
Overall cost [B] 80.32 (82.48) 84.37 (31
1 Estimated for the 12 weeks preceding intervention, using 2 week baseline data an
2 Twelve weeks while receiving the patient support programme.
3 Difference in costs in the two periods (negative denotes a reduction).
4 Estimated by bootstrapping with 1,000 replications.
A Emollient use costed using the daily diary method.
B Emollient use costed using the estimated time taken to use a 500 g pot of emollimight consider an appropriate local adaptation of the ESP
to address patients’ needs, while accepting the need not to
subtract from the components, which may work synergis-
tically. Details of the ESP are available online to assist
those developing services [22]. Education regarding the
use of topical products including emollients is an essential
part of the management of many other skin diseases such
as psoriasis [26]. Similar ESPs to that evaluated in this
study for atopic eczema could enhance adherence with
topical treatment regimens and improve outcomes in these
skin diseases.
Topical steroid prescriptions increased during the study,
although it is unlikely that steroid use profoundly affected
the study findings. In common with our clinical experi-
ence, parents in the study reported using steroids minim-
ally and change in availability only occurred in 20% of
patients. However, volume of use of prescriptions was not
measured formally.
Two measures within the study captured aspects of
the impact of childhood eczema on the broader family.
Increased emollient use was significantly related to
reduced sleep disturbance and greater sense of parental
control through a greater understanding of the disease
and their child’s symptoms. Parents expressed frustration
at the inconsistency of information and advice provided
in primary care about eczema and its management. A
qualitative analysis of patient narratives will be published
separately.
Within the duration of the programme the overall cost
was cost-neutral while providing tangible health benefits
to children and their families. It is likely that cost savings
would continue to accrue beyond the duration of the
study hence the within-programme analyses presented
should be viewed as conservative. If savings are extrapo-
lated then, under a range of assumptions, the ESP is likely
be both cost saving and symptom-reducing in children
with mild to moderate atopic eczema.Change3,4
D) Mean 95% CI4 N p
- 32.00 - - -
.03) 10.28 (7.93 to 12.64) 132 0.001
.21) 12.91 (10.72 to 15.10) 115 0.001
.67) −38.13 (−52.58 to −23.68) 135 0.001
.16) 4.37 (−10.55 to 19.30) 132 0.62
.29) 4.06 (−12.00 to 20.11) 115 0.56
d 12 week recall (GP visits).
ent.
Table 3 Sensitivity analysis: excluding children who had recently seen a specialist
Pre-Programme1 Programme2 Change3,4
Mean (SD) Mean (SD) Mean 95% CI4 N p4
Emollient Use (g/wk)
Daily diary 69.7 (49.5) 170.3 (99.0) 100.6 (81.9 to 119.5) 114 0.001
Time to use 72.2 (49.6) 184.3 (97.6) 112.2 (94.6 to 131.3) 99 0.001
Severity Scores
POEM 11.03 (6.49) 5.83 (4.67) −5.20 (−6.39 to −4.34) 117 0.001
PEST 2.26 (0.82) 1.66 (0.62) −0.60 (−0.74 to −0.47) 117 0.001
Cost (£, 2011)
Programme 32.00 - 32.00 - - -
Emollient [A] 8.18 (5.80) 19.98 (11.61) 11.81 (9.81 to 14.01) 114 0.001
Emollient [B] 8.47 (5.82) 21.63 (11.46) 13.16 (10.94 to 15.39) 99 0.001
GP visits 63.23 (63.80) 30.46 (30.86) −32.77 (−45.77 to −19.77) 117 0.001
Overall cost [A] 71.81 (66.37) 83.25 (33.75) 11.44 (−1.99 to 24.86) 114 0.123
Overall cost [B] 72.11 (68.24) 83.45 (33.75) 11.35 (−3.14 to 25.83) 99 0.239
1 Estimated for the 12 weeks preceding intervention, using 2 week baseline data and 12 week recall (GP visits).
2 Twelve weeks while receiving the patient support programme.
3 Difference in costs in the two periods (negative denotes a reduction).
4 Estimated by bootstrapping with 1,000 replications.
A Emollient use costed using the daily diary method.
B Emollient use costed using the estimated time taken to use a 500 g pot of emollient.
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While introduction of the ESP provided a strong contem-
poraneous improvement in emollient treatment and
subsequent atopic eczema symptoms, the study design
lacked the protection against bias afforded by a
randomised controlled design. The major threat to attri-
bution is regression to the mean where a concerned sub-
group of parents enrol children with naturally recurring
and remitting eczema at a point of acute symptoms, which
tend naturally to lessen. A control group selected by
randomisation would separate out programme and regres-
sion effects. However the changes in emollient use and in
measures of eczema severity are dramatic, consistent and
contemporaneous with the programme and are thus likely
to preclude a pure regression effect. A further threat lies
in the generalizability of findings if a highly selected popu-
lation with atypical characteristics (in the parent or child)
have volunteered to participate in the study, although this
is mitigated by the broad inclusion by ethnicity and socio-
economic group. Finally, parents were asked to recall visits
to primary care and specialists in the 12 weeks preceding
baseline, a long period of recall potentially introducing
recall bias.
Conclusions
The educational support programme (ESP) provided
coherent messaging and support to parents and their
children with atopic eczema. During the 12 week course
of the programme there was a dramatic and significant
increase in emollient use and also a small associatedincrease in mild potency steroid use. The ESP dramatically
reduced signs of eczema, sleep disturbance and parental
feelings of lack of control. Analysis at 12 weeks provides
evidence that the ESP is a cost-neutral strategy although
this will be further explored at 12 months. A new, simple
measure of eczema severity (PEST score) designed to help
parents and children to monitor and manage eczema
showed similar sensitivity and high correlation with the
POEM [23] measure, and thus merits further evaluation.
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